Industrial Policy & Trade Monitor· 2665 actions· ✨ 90 recent

On June 8, 2026, the US Department of Defense published its annual update to the Section 1260H Chinese Military Companies (CMIC) list, adding 65 entities (17 new parent companies and 48 subsidiaries), bringing the total to approximately 188–200 designated entities. Major additions span EV and battery manufacturing (BYD, NIO, CATL), consumer internet (Alibaba, Baidu, Tencent), semiconductors (SMIC, YMTC, CXMT), solar (JA Solar, Trina Solar), biotech (BGI Genomics, WuXi AppTec), drones/robotics (DJI, Unitree, RoboSense), and telecoms (TP-Link). Effective June 30, 2026, DoD is prohibited from procuring goods, services, or technology directly from listed entities; effective June 30, 2027, the ban extends to indirect supply-chain procurement through prime contractors and all sub-tiers.

On 8 May 2026 China's National Health Commission released a public consultation draft proposing material amendments to the 2023 Implementation Rules for the Administrative Regulations on Human Genetic Resources, with a comment deadline of 7 June 2026. The draft narrows the statutory "foreign party" definition to a bright-line 50% equity/voting threshold (excluding VIE-structured entities), restricts "HGR Information" strictly to nucleic-acid sequence data (excluding clinical, imaging, and metabolic data), removes the separate Article 37 security-review requirement for sensitive HGR datasets, and introduces a same-day or next-working-day fast-track confirmation for international clinical trials not involving HGR information export.

South Korea's 13th National Strategic Technology Special Committee (chaired by MSIT) adopted the 2026 Annual Implementation Plan for the First Basic Plan for National Strategic Technology Development (2024–2028), committing KRW 8.6 trillion in 2026 R&D investment — a ~30% YoY increase from KRW 6.5 trillion in 2025 — across 19 NEXT strategic-technology fields encompassing AI, semiconductors, quantum, displays, and secondary batteries, coordinated across 23 ministries. The plan is supplemented by KRW 46.6 trillion in policy finance delivered through Korea Development Bank (KDB), Industrial Bank of Korea (IBK), Korea Credit Guarantee Fund (KCGF), and Korea Technology Finance Corporation (KOTEC), providing the horizontal funding-coordination architecture that operationalises all sector-specific Korean strategic-technology legislative instruments.

The US Department of Commerce published its final affirmative determination of sales at less-than-fair-value in the antidumping investigation of animal feed-grade L-lysine (lysine) from China (case A-570-215) on 23 July 2026, following a preliminary determination published 6 March 2026 (91 FR 11030). Commerce found a China-wide weighted-average dumping margin of 139.83% (cash deposit rate 139.65% after subsidy-offset adjustment), based on adverse facts available after Commerce found Zhengzhou Longgu Trading Co., the sole company with a calculated margin, and the Eppen Group group of producers/exporters uncooperative and ineligible for a separate rate in the final determination. A group of separate-rate companies — including Anhui BBCA Biochemical, Heilongjiang Wanlirunda Biotechnology, and others exporting through trading intermediaries such as Agromate Sg, Ainore (Tianjin), and Aollen Biotech — received a 73.55% dumping margin (73.37% cash deposit rate). The order covers lysine regardless of form (HCl, sulfate, liquid) under HTSUS 2922.41.0090 and related subheadings. A companion countervailing-duty investigation (preliminary 22 January 2026, 91 FR 2745) was finalized the same day; suspension of liquidation runs from 6 March 2026, with a final AD order contingent on an ITC injury determination due within 45 days of the final LTFV finding.

Gujarat Chief Minister Bhupendra Patel launched the Gujarat Science, Technology and Innovation (STI) Policy 2026–2031 on 1 March 2026 at the SemiConnect 2026 Conference in Gandhinagar, establishing a five-year ₹1,000 crore Swadeshi Anusandhan Fund (Indigenous Innovation Fund) for domestic R&D across strategic sectors including AI, semiconductors, quantum technologies, biotechnology, green energy, and defence. The policy targets state STI expenditure of 1% of GSDP by 2030, creation of 1 lakh skilled research professionals, 1,000+ IP filings annually, and builds three Gujarat Rajya Research and Innovation Cluster (GRRIC) corridors to anchor the state's growing semiconductor manufacturing ecosystem.

The US Department of Commerce published its final affirmative countervailing-duty (CVD) determination on animal feed-grade L-lysine from China (case C-570-216) on 23 July 2026, the companion subsidy proceeding to the parallel antidumping case (A-570-215) finalized the same day. Commerce found Heilongjiang Wanlirunda Biotechnology Co., Ltd. and Shouguang Golden-land Industry & Trading Co., Ltd. received countervailable subsidies at 82.11%, while Inner Mongolia Eppen Biotech Co., Ltd. and all other Chinese producers/exporters were assigned a 48.21% subsidy rate. The preliminary CVD determination, published 22 January 2026, set the initial cash-deposit rates and suspension of liquidation; the final determination confirmed and aligned the case with the AD final determination for a joint ITC injury vote.

Section 851 of the FY 2026 National Defense Authorization Act (P.L. 119-60), signed December 18, 2025, prohibits US federal agencies from procuring biotechnology equipment or services from designated "biotechnology companies of concern" (BCCs), and bars federal contractors from using such equipment/services in work performed under federal contracts, grants, or loans. The final enacted text ties initial BCC designations to DoD's existing §1260H Chinese-military-company list (which currently includes BGI and MGI, but not WuXi AppTec or WuXi Biologics) and directs OMB to designate additional BCCs within one year of enactment; operational prohibitions activate 60-90 days after FAR revision, with a five-year grandfather period for pre-existing contracts — enforcement is expected to begin in 2027-28. The legislation is the successor to H.R.8333 (118th Congress, House-passed September 2024 but stalled in the Senate before adjournment) and represents the first enacted US federal-procurement biotech-supply-chain-resilience statute.

On 16 December 2025 the European Commission adopted in Strasbourg the Proposal for a Regulation establishing a framework of measures for strengthening the Union's biotechnology and biomanufacturing sectors particularly in the area of health — the "European Biotech Act" (COM(2025) 1022 final). The proposal is the third axis of the EU's pharma/biotech industrial-policy stack alongside the Critical Medicines Act (filed: 2025-03-11-eu-critical-medicines-act-proposal) and the US Section 232 pharmaceuticals track (filed: 2026-04-02-us-section-232-pharmaceutical-proclamation), and is explicitly designed to keep biotech innovation, investment, and biomanufacturing capacity in Europe in the face of US/China competitiveness pressure. Core instruments: (1) statutory recognition for "Health Biotechnology Strategic Projects" (HBSPs) and "High-Impact" HBSPs eligible for accelerated permitting via a single national contact point, plus administrative/technical/ financial support; (2) regulatory sandboxes for novel biotech and biomanufacturing modalities; (3) a 12-month Supplementary Protection Certificate extension for qualifying biotech and advanced-therapy medicines; (4) targeted simplification of existing EU life-sciences acquis (clinical-trial timelines, risk-proportionate requirements); (5) an EU Health Biotechnology Investment Pilot co-developed with the EIB Group, paired with a EUR 10bn 2026-27 EIB-Commission financing initiative; (6) biosecurity safeguards including a list of "biotechnology products of concern" and mandatory built-in screening for benchtop nucleic-acid synthesis devices. A second tranche covering industrial biotechnologies and biomanufacturing outside health is expected later in 2026.

Japan's Cabinet adopted a Cabinet Order on 11 November 2025 (promulgated 14 November 2025, effective 14 February 2026) amending Appended Table 1 of the Export Trade Control Order (輸出貿易管理令) to add three new list-control item categories: (i) peptide synthesizers and related components (Item group mapping to Australia Group 2023–2024 plenary dual-use biotechnology controls, aligning Japan with the US BIS implementation promulgated December 2024), (ii) powders of refractory metals or their alloys below specified particle-size and purity thresholds — tungsten, molybdenum, niobium, tantalum, and rhenium powders used as additive- manufacturing feedstocks (Item 5(20), implementing a Wassenaar Arrangement plenary outcome on metal-powder dual-use), and (iii) modules, assemblies, or devices incorporating field-programmable logic devices (FPGAs) above specified gate-count and process-node thresholds (Item 7(10-2), extending Japan's semiconductor-component AI-compute perimeter). This is the first discrete Appended Table 1 list-control amendment filed under the post-October-2025 FEFTA catch-all- controls overhaul architecture.

The National Reconstruction Fund Corporation (NRFC), Australia's AUD 15 billion sovereign industrial-financing vehicle, took a AUD 54 million (~USD 35 million) equity stake in Synchron, a Melbourne-founded (now US-headquartered) brain-computer interface company, announced 7 November 2025. The investment forms part of Synchron's broader ~AUD 305-308 million (~USD 200 million) Series D raise alongside investors including Qatar Investment Authority, In-Q-Tel and Double Point Ventures, and is earmarked to fund final clinical trials and US FDA regulatory approval of Synchron's Stentrode device — a minimally-invasive BCI implanted via blood vessel without open brain surgery. NRFC frames the deal as commercialising Australian-origin technology and building sovereign medical-device manufacturing and clinical-trial capability.

The Chongqing Municipal People's Government General Office issued "Several Measures for Chongqing's Full-Chain Support of High-Quality Innovative Drug Development" (Yu Fu Ban Fa [2025] No. 56) on 2025-11-01, a 25-point package of regulatory-fast-track and procurement-support measures for the municipal biopharma sector. It targets 1-3 newly approved innovative drugs per year through 2027 (10 total) and the cultivation of 3 pharmaceutical-innovation industrial complexes, 3 high-level innovation platforms, and 3 innovative-drug industry clusters. No direct subsidy or tax-incentive amount is disclosed in the published text — the package is operational (compressed clinical-trial and registration timelines, guaranteed hospital procurement) rather than a cash grant.

On 28 October 2025, Saudi Arabia's Local Content & Government Procurement Authority (LCGPA) signed five localization and knowledge-transfer agreements on the sidelines of the Global Health Exhibition 2025, covering domestic manufacture and technology transfer for the biologic drugs etanercept and adalimumab (both used to treat chronic inflammatory / autoimmune conditions) and for orthopedic trauma implants. The adalimumab agreement was signed separately with Boston Oncology Arabia and Tabuk Pharmaceuticals. Boston Oncology's own disclosure of its adalimumab/ etanercept agreement (announced 4 November 2025) put the combined economic impact at over SAR 1.2 billion in cumulative GDP contribution and approximately 500 direct jobs, with production sited at its Sudair Industrial City facility (USFDA/EMA/SFDA-standard). Global Trade Alert's tracking of the same state act records seven counterparties in total (Boston Oncology, Tabuk Pharmaceuticals, Rameem Medical, Bio Vision, Sudair Pharma, Almana Company, and an additional pharma manufacturer), consistent with LCGPA's practice of bundling several related product-localization signings into one event.

The UK Department for Science, Innovation and Technology and the Office for Life Sciences launched the Life Sciences Transformational R&D Investment Fund (TRIF) Pilot, a GBP 50 million (approx. USD 67.4 million) capital grant scheme for large-scale R&D projects in the life sciences sector. Only projects with total costs of at least GBP 100 million qualify, with grants typically covering 10-20% of total project costs. The pilot runs on a rolling-application basis until 31 March 2028 or until funding is exhausted.

On 17 September 2025 the General Office of the Shanghai Municipal People's Government issued Hufubangui [2025] No. 8, a five-year (26 September 2025 - 25 September 2030) state-aid framework to accelerate frontier-technology innovation and cultivate "future industries" across six domains — future manufacturing, future information, future materials, future energy, future space and future health. Targeted technology areas include cell and gene therapy, brain-computer interfaces, biomanufacturing, embodied intelligence (humanoid robotics/AI hardware), fourth-generation semiconductors, silicon photonics, 6G, neuromorphic computing, quantum technology, controlled nuclear fusion and regenerative medicine. Support is disbursed as tiered direct subsidies rather than tax relief, with named ceilings up to CNY 30 million per proof-of-concept/R&D platform and CNY 20 million per high-quality incubator or first-product/batch innovation award.

The Bureau of Industry and Security (BIS) amended the Export Administration Regulations (EAR) to add 32 entities to the Entity List, with the largest bloc — 23 entries — under the destination of China, plus India (1), Iran (1), Singapore (1), Taiwan (1), Turkey (3), and the United Arab Emirates (2). The rule also removed two addresses from one Russian entry (Intertech Rus LLC) and made 27 typographical corrections to existing entries. Several Chinese additions — including Shanghai Fudan Microelectronics, Sino IC Technology, GMC Semiconductor (Wuxi), and Chinese Academy of Sciences units (National Time Service Center; Aerospace Information Research Institute) — were given footnote 4 designations, extending the EAR's foreign-direct-product (FDP) reach to non-US-origin items destined for Russian military end use. Three Turkish entries (Atempo, EB Teknoloji, Dentun Elektronik) and one Indian entry (AR Sales Pvt Ltd) were footnote-3 Russian Procurement Entity designations. The rule is a final rule effective September 12, 2025; all listed parties are subject to a license requirement for all items subject to the EAR with a presumption-of-denial review policy.

On 29 August 2025 the Pinggu District (Beijing) Science, Technology and Economic Informatization Bureau issued "Several Measures to Promote the High-Quality Development of High-End Manufacturing in Pinggu District" (平谷区促进高端制造业高质量发展若干措施), published to the district government portal on 25 September 2025 with a two-year validity period. The scheme offers manufacturers registered and operating in Pinggu a stack of output-growth, R&D, smart-factory, green-transformation, pharma/medical- device, auto-parts-supply-chain, and synthetic-biology subsidies, with per-recipient caps ranging from RMB 200,000 up to RMB 10 million for qualifying pharmaceutical/medical-device innovators.

The Hainan Provincial People's Government General Office issued "Several Policy Measures of Hainan Province for Further Supporting High-Quality Development of the Biopharmaceutical Industry" (Qiong Fu Ban [2025] No. 38) on 2025-08-14, effective 2025-09-13 for a three-year term. The package disburses provincial subsidies across the full biopharma value chain — R&D-stage grants, national centralized-procurement awards, international-certification bonuses, platform-investment reimbursement, and traditional-Chinese-medicine insurance-listing awards — leveraging Hainan Free Trade Port status to build a regional biomedical industry cluster.

Banque des Territoires, acting on behalf of the French State under the France 2030 programme, launched a EUR 500 million fund-of-funds called "Global Tech Coté" on 7 August 2025. The vehicle takes minority stakes (EUR 15 million minimum, capped at 10% of a target fund's subscribed capital) in privately-managed investment funds that in turn back publicly-listed French technology companies with strong growth potential, aiming to build up domestic asset-management capacity alongside the state's stated goal of channelling capital into equities. The selection window for management companies runs until 31 December 2026 or until the EUR 500 million envelope is exhausted, whichever comes first.

The National Reconstruction Fund Corporation (NRFC), Australia's AUD 15 billion sovereign industrial-financing vehicle, committed AUD 150 million to Brandon Capital's Brandon BioCatalyst 6 (BB6) fund, announced 24 July 2025. Brandon Capital — Australasia's largest life-sciences venture capital manager, with over AUD 1 billion under management — closed BB6 at AUD 439 million total, with the NRFC contribution the largest single commitment. The fund backs early- and late-stage Australian medical-science companies developing therapeutics, medical devices and vaccines, with roughly one-third earmarked for early-stage ventures and the remainder for late-stage clinical development and commercialisation. NRFC frames the deal as building sovereign medical-manufacturing and R&D capability and keeping Australian biotech IP and jobs onshore rather than migrating offshore for follow-on capital.

On 22 July 2025, BNDESPAR — the equity-investment arm of Brazil's national development bank BNDES — approved a BRL 114 million (approx. USD 20.5 million) minority equity subscription in Grupo Santa Clara, a Ribeirão Preto (São Paulo)-based producer of special fertilizers and bioinputs founded in 1997. The deal gives BNDESPAR a 19.9% stake, implying a company valuation near BRL 570 million, and is BNDESPAR's first direct variable-income (equity) operation since the bank reactivated its equity-participation strategy in June 2025 — a decade after its last direct stock investment. Proceeds are earmarked to expand Santa Clara's biofactory in Jaboticabal (SP) and fund the group's growth plan toward BRL 1 billion in revenue by 2030.

On 1 July 2025 India's Union Cabinet approved the Research Development and Innovation (RDI) Scheme, a six-year, ₹1,00,000 crore (≈USD 11.68 bn) fund to catalyse private-sector investment in research, development and innovation, with ₹20,000 crore allocated for FY2025-26. The scheme finances transformative RDI projects (TRL 4 and above) in strategic and sunrise sectors — deep tech, AI, biotechnology, quantum computing, robotics, space, energy transition and the digital economy — through long-tenor, low-or-nil-interest loans and equity, up to 50% of assessed project cost. Grants and short-term loans are explicitly excluded. Funds flow through a Special Purpose Fund under ANRF (first-level) to second-level fund managers — Alternate Investment Funds, Development Finance Institutions, NBFCs, and focused research bodies including the Technology Development Board (TDB) and BIRAC — which began issuing project calls in February 2026.

On 23 June 2025, BNDES president Aloizio Mercadante announced that BNDESPAR — the equity-investment arm of Brazil's national development bank — would resume direct variable-income (equity) investing after roughly a decade, committing up to BRL 10 billion (~USD 1.8bn) to companies and funds focused on ecological transition, decarbonization and innovation. The commitment splits into up to BRL 5 billion in direct equity investments (open to applicants through December 2025) and up to BRL 5 billion deployed via investment funds, funded from proceeds of BNDESPAR's sale of mature-company stakes and dividend receipts rather than new fiscal outlay. The bank framed the relaunch as strengthening Brazil's capital markets while directing state capital toward green-economy and innovation targets of all company sizes.

Slovakia's Office of the Deputy Prime Minister for the Recovery Plan and Knowledge Economy approved a EUR 160 million state-aid scheme ("Schéma štátnej pomoci na podporu znalostnej ekonomiky, výskumu, vývoja a inovácií") on 4 June 2025 to fund business-sector research, development and innovation projects, with emphasis on experimental development and industrial research. The office subsequently opened two calls under the scheme, in biotechnology and in robotics/automation, on 16 June 2025 (deadline 16 August 2025); demand of 338 project proposals worth over EUR 800 million led the office to raise the allocation for those two calls from EUR 180 million to roughly EUR 230 million. Supported projects run through 2027.

The National Reconstruction Fund Corporation (NRFC), Australia's AUD 15 billion sovereign industrial-financing vehicle, took a AUD 27 million equity stake in PolyActiva, a Melbourne biotech developing a biodegradable ocular implant (Prezia/PA5108) that delivers glaucoma medication over 6-12 months as an alternative to daily eye drops. The investment, announced 30 May 2025, forms the majority of PolyActiva's AUD 40 million Series C round, with the remaining AUD 13 million from existing investor Brandon Capital. Funds will consolidate the company's R&D, analytics and manufacturing into a single Melbourne facility, grow its ~25-person workforce, and fund completion of a Phase 2b clinical trial, with commercialisation targeted for 2029.

The UK Department for Science, Innovation and Technology signed a grant agreement with BioNTech UK Ltd. providing up to GBP 129 million in government support over 10 years, underpinning BioNTech's planned GBP 1 billion (USD 1.3 billion) investment in UK research and development over the same period. The funding backs two new R&D hubs: a life-sciences research centre in Cambridge (genomics, oncology, structural biology, regenerative medicine) and an AI hub co-located with BioNTech's planned UK headquarters in London, run by its InstaDeep subsidiary. The government frames the deal as one of the largest single-company investments in UK life-sciences history and part of the Oxford-Cambridge Growth Corridor and Plan for Change industrial strategy.

On 30 April 2025 the General Office of the Guangdong Provincial People's Government issued Yue Fu Ban [2025] No. 11, "Several Measures of Guangdong Province to Further Stimulate Market Entity Vitality and Accelerate the Construction of a Modern Industrial System," effective immediately through 31 December 2027. The package subsidizes bank-loan interest for manufacturing and high-tech enterprises at up to 35% of the loan rate, capped at RMB 2 billion in total annual subsidy volume and RMB 20 million per enterprise per year, alongside an expansion of government-backed financing-guarantee coverage to over RMB 10 billion annually. It also funds foreign-invested R&D centers (up to RMB 1 million, or RMB 5 million for multinational global R&D centers) and offers headquarters-relocation bonuses of up to RMB 8 million, with priority given to semiconductors, AI, robotics, biotechnology, quantum technology, commercial aerospace, and new-energy vehicles.

On 27 February 2025, the Parliament of the Republic of Moldova adopted Law No. 33/2025 amending Law No. 174/2021 on the mechanism for examining investments of importance for state security. The law entered into force on 20 April 2025 after publication in Monitorul Oficial Nr. 144-147 of 20 March 2025 (promulgated by Presidential Decree No. 118-X of 17 March 2025). Key operative changes expand the protected-sector perimeter to explicitly enumerate 17 categories covering data processing and storage, AI, robotics, cybersecurity, semiconductors, quantum, nanotechnology and biotechnology alongside the pre-existing energy, transport, communications, defence and aerospace pillars; add new grounds for refusal (money-laundering suspicion, corruption convictions, foreign-government control, cybersecurity risk, access to personal data of citizens); introduce enhanced Council powers including retroactive review of previously approved investments and fines of up to 5% of annual turnover (capped at MDL 5 million); and carve out intra-group transactions, asset sales below EUR 1 million, and state-owned-enterprise dealings. The Screening Council became operational in July 2025.

On 19 February 2025 Vietnam's 15th National Assembly adopted Resolution 193/2025/QH15 at its 9th Extraordinary Session, establishing 12 pilot policy categories that operationalise the Politburo's December 2024 Resolution 57-NQ/TW without requiring full-statute enactment. The resolution's most structurally novel element is an R&D risk-acceptance framework — the first in Southeast Asia — that exempts organisations and individuals from civil liability for damage caused to the State in the course of state-funded R&D activities conducted in compliance with prescribed procedures, directly addressing Vietnam's long-standing chilling effect on state-sector innovation. Additional pilots cover expedited procurement for sci-tech and digital-transformation projects, special tax and immigration incentives for high-skilled AI/semiconductor/ quantum R&D personnel, accelerated permitting pathways for priority-sector R&D investments, a start-up grant and venture framework, and an open-data regime for state-held datasets. Implementing Decree 88/2025/ND-CP was issued shortly after adoption; the resolution provides the legal-framework architecture that complements the financial-instrument side (Decree 182/2024/ND-CP, VND 30 trillion Investment Support Fund) and the sectoral-law cluster enacted in late 2025.

China's Unreliable Entity List (UEL) Working Mechanism, led by MOFCOM, issued Announcement [2025] No. 2 on 4 February 2025, designating PVH Group (parent of Calvin Klein and Tommy Hilfiger) and Illumina Inc. (US genomics / gene-sequencing equipment maker) as Unreliable Entities under the 2020 UEL Provisions, citing violations of normal market-transaction principles and discriminatory measures against Chinese enterprises. PVH was cited for its Xinjiang-cotton sourcing boycott (MOFCOM probe launched September 2024); Illumina was cited for restricting Chinese customers' access to gene-sequencing equipment. The announcement was issued on the same day as China's IEEPA-retaliation tariff package (10–15 % on US coal, LNG, crude oil, agricultural goods, and autos), making it the first UEL listing of a Western consumer-brand / retail company and the first combining a UEL designation with a subsequent sector-specific export prohibition (gene sequencers, imposed 28 February 2025).

The National Assembly of the Republic of Korea passed on 27 December 2024 a comprehensive amendment to the Act on Prevention of Divulgence and Protection of Industrial Technology (산업기술의 유출방지 및 보호에 관한 법률, the "ITA" or "Industrial Technology Protection Act"), effective 22 July 2025. The amendment grants MOTIE direct statutory authority to block or reverse unapproved exports and overseas transactions involving National Core Technologies (NCTs) — including M&As, technology-transfer transactions, and foreign-investment events — without requiring interdepartmental coordination that was necessary under prior enforcement-decree authority. Entities already verified as NCT holders must complete formal registration with MOTIE within six months of the effective date (by approximately 22 January 2026). Punitive damages for wilful NCT infringement are raised from 3x to 5x actual damages, and criminal fines for overseas NCT leakage are raised from KRW 1.5 billion to KRW 6.5 billion.

Vietnam's 15th National Assembly passed Law 44/2024/QH15 on 21 November 2024, comprehensively amending the 2016 Law on Pharmacy. The law liberalises foreign-invested enterprise (FIE) rights — permitting FIEs to wholesale self-imported drugs and APIs and to operate pharmacy chains for the first time — while introducing a special investment-incentive tier for pharma projects capitalised at ≥ VND 3,000 billion (≈ USD 120m) with ≥ VND 1,000 billion disbursed within three years. Online retail of non-prescription drugs is formally legalised as a distinct regulated business activity. Most provisions take effect 1 July 2025; selected marketing-authorisation renewal procedures took effect 1 January 2025. Implementing Decree 163/2025/ND-CP, effective 1 July 2025, provides detailed operational guidance.

On 26 July 2024 President Erdoğan unveiled the HIT-30 (High-Technology Investment Programme), Türkiye's largest single industrial-finance instrument since the 2018 Investment Office reform, allocating USD 30 billion in state support over 2024-2030 to attract investment across 37 priority programmes spanning electric vehicles, batteries, semiconductors, solar/wind energy, green hydrogen, hyperscale data centres, biotechnological medicine, industrial robotics, and R&D. The Ministry of Industry and Technology is the operating agency, with the Industrialization Executive Committee chaired by the President providing high-level oversight; an Industrialisation Executive Committee under the President directs sectoral allocations. Headline tools include USD 4.5bn earmarked for an 80 GWh battery-manufacturing capacity (with USD 6,000/MWh grants through 2030), USD 2.5bn for 15 GW of domestic solar-cell capacity, USD 1.7bn for wind-component manufacturing, USD 1bn for top-1000 corporate R&D centre support (covering 50% of personnel costs for 5 years), corporate tax reductions, social-security-contribution coverage, energy-cost subsidies covering 50% of bills for energy-intensive projects, customs/VAT exemptions, and free or discounted land allocation in organised industrial zones. Programme targets at least USD 20bn in private-sector co-investment.

On 26 February 2024, President Ferdinand Marcos Jr. signed Republic Act No. 11981 ("Tatak Pinoy Act"), the first standalone national industrial policy law in Philippine history. It mandates the formulation, funding, implementation, monitoring, and evaluation of a multi-year Tatak Pinoy Strategy organised around five pillars (human resources, infrastructure, technology and innovation, investments, sound financial management) and establishes the Tatak Pinoy Council, chaired by the DTI Secretary with NEDA and Finance secretaries as vice-chairs. On 24 October 2025, Marcos issued Memorandum Circular No. 104 approving the implementing Tatak Pinoy Strategy and directing all national agencies, GOCCs, and LGUs to prioritise local products in procurement, with local suppliers eligible for award if their bids are within 25% of the lowest foreign offer.

Bulgaria's National Assembly adopted on 22 February 2024 amendments to the Investment Promotion Act establishing the country's first horizontal foreign direct investment screening mechanism, published in State Gazette No. 20 on 8 March 2024 and entering into force on 12 March 2024. The regime implements EU Regulation 2019/452 by creating an Interdepartmental Screening Council with a 45-day decision window over non-EU investments meeting a 10 % equity stake or €2 million threshold in critical-infrastructure, dual-use, advanced-technology, media, and financial-infrastructure sectors, with no threshold for investments by Russian or Belarusian persons or in oil and petroleum activities. Non-compliance and false declarations carry fines of 5 % of investment value, with a minimum BGN 50,000.

Ireland's Screening of Third Country Transactions Act 2023 (Act No. 28 of 2023), signed into law on 31 October 2023 and commenced on 6 January 2025 via S.I. No. 651 of 2024, establishes Ireland's first-ever mandatory inbound FDI screening regime. The Act empowers the Minister for Enterprise, Tourism and Employment to assess, condition, or prohibit transactions by third-country investors (non-EU/EEA/Switzerland) exceeding a EUR 2 million cumulative threshold in targets operating across critical infrastructure, critical technologies, dual-use items, supply of critical inputs, sensitive personal data, and media freedom. A 90-day standstill period applies during Ministerial determination, with criminal sanctions and transaction-voiding powers available for non-compliance.

Luxembourg's Chambre des Députés adopted the first-ever national FDI-screening statute on 14 July 2023 (promulgated by the Grand Duke and published in Mémorial A n° 411 on 18 July 2023), entering into force 1 September 2023. The law requires non-EU investors to notify the Ministre de l'Économie before completing direct or indirect acquisitions of ≥25% voting rights / equity in Luxembourg entities engaged in "critical activities" across twelve sectors. The Minister can approve, conditionally approve, or prohibit transactions within a two-month initial screening window, with a further 60-day deep-review phase available; an inter-ministerial Comité de filtrage (Economy + Foreign Affairs + Finance + SREL intelligence service) advises on security and public-order grounds consistent with EU Regulation 2019/452.

The Foreign Investment Reliability Assessment Act (välismaise investori usaldusväärsuse hindamise seadus, VUHS), adopted by the Riigikogu on 25 January 2023 and in force from 1 September 2023, establishes Estonia's first horizontal ex-ante foreign direct-investment screening regime. The Act transposes EU Regulation 2019/452 into Estonian law and designates the Consumer Protection and Technical Regulatory Authority (Tarbijakaitse ja Tehnilise Järelevalve Amet — TTJA) as the screening authority. It covers acquisitions of qualifying holdings or material influence in target undertakings operating in defence, dual-use, vital services, energy and communications infrastructure, transport, financial services, media, critical raw materials extraction and other strategic sectors. TTJA can prohibit, condition or unwind non-compliant transactions and impose administrative non-compliance levies.

Commission Delegated Regulation (EU) 2023/66, adopted 21 October 2022 and published in the Official Journal on 11 January 2023 (OJ L 9), replaces Annex I of Regulation (EU) 2021/821 (the EU Dual-Use Recast Regulation) with an updated control list implementing the 2022 multilateral decisions of the Wassenaar Arrangement, MTCR, Australia Group, NSG and the Chemical Weapons Convention. Per GTA's tracking of the CN-code-level change, the update removed 7 six-digit CN codes and added 8 new ones. It entered into force on 12 January 2023, the day after publication.

Act No. 497/2022 Coll. on the Screening of Foreign Investments and on amendments to certain acts, adopted by the National Council of the Slovak Republic on 29 November 2022 and promulgated in the Zbierka zákonov on 23 December 2022, established Slovakia's first horizontal ex-ante foreign-direct-investment screening regime. The Act took effect on 1 March 2023, transposing EU Regulation 2019/452 into Slovak law and replacing the prior sector-specific approach under Act No. 45 on critical infrastructure. Screening is administered by the Ministry of the Economy of the Slovak Republic across three procedures (mandatory, voluntary, and ex officio) and covers transactions in defence, dual-use, critical infrastructure, critical raw materials, biotechnology, AI, semiconductors and other emerging technologies. The Ministry can prohibit, condition or unwind non-compliant transactions and impose administrative penalties.

The Bureau of Industry and Security (BIS) amended the Export Administration Regulations (EAR) on 8 February 2022 to add 33 persons — all based in China — to the Unverified List (UVL) under EAR §744.15(c), on the basis that BIS could not satisfactorily complete end-use checks for these entities for reasons outside US Government control. Placement on the UVL bars exporters from using any EAR license exception when shipping controlled items to listed parties and requires exporters to obtain a certified UVL Statement from the entity or secure a BIS export licence. Sectors represented include semiconductor manufacturing equipment, optoelectronics, UAVs, specialty chemicals, and biotechnology.

The US Bureau of Industry and Security (BIS) amended the Export Administration Regulations (EAR) by adding 37 entities under 40 entries to the Entity List, effective December 17, 2021. The additions span three distinct threat rationales: (1) support for Chinese military modernization across semiconductors, submarine cables, armored vehicles, and defense electronics; (2) the Academy of Military Medical Sciences and 11 affiliated institutes pursuing biotechnology processes for military end uses, including purported brain-control weaponry under EAR §744.11(b); and (3) a cross-border Iran sanctions-evasion network operating across China, Georgia, Malaysia, and Turkey that diverted US-origin items to Iran's defense industries and advanced conventional weapons programs. All 40 entries carry a presumption-of-denial licensing policy for all items subject to the EAR, with no license exceptions available.

France 2030 is a €54 billion public investment plan unveiled by President Emmanuel Macron on 12 October 2021 to fund breakthrough innovation and reindustrialisation across ten strategic priorities — small modular nuclear reactors, green hydrogen, low-carbon transport (incl. two million EVs/year), food/agritech, twenty drug therapies for cancer and chronic disease, cultural industries, space, deep-sea exploration, semiconductors and electronic components, and robotics/digital (AI/cloud). Two cross-cutting rules require 50% of investment to flow to decarbonisation and 50% to emerging innovative players. Operationalised from the 2022 budget law, the plan is coordinated by the Secrétariat général pour l'investissement (SGPI) under the Prime Minister and delivered by ANR, ADEME, Bpifrance and Caisse des Dépôts / Banque des Territoires.

Regulation (EU) 2021/821, adopted 20 May 2021 and applied from 9 September 2021, establishes the Union regime for controlling exports, brokering, technical assistance, transit, and transfer of dual-use items, repealing Regulation (EC) No 428/2009. Annex I lists controlled items implementing internationally agreed dual-use controls under the Wassenaar Arrangement, MTCR, Australia Group, NSG, and Chemical Weapons Convention. The regulation introduces a new catch-all control on cyber-surveillance technologies that could facilitate human-rights violations (Art. 5 and Annex IV), and strengthens cooperation between Member States and the European Commission, placing specific obligations on exporters. It serves as the statutory anchor for all EU export licences, every multilateral-regime transposition into EU law, and coordination mechanisms with US BIS, UK ECJU, JP METI, and KR MOTIE export-control regimes.

The modern French FDI-screening regime is codified in Code monétaire et financier (CMF) Art. L151-1 to L151-7, substantially restructured by Loi PACTE n° 2019-486 du 22 mai 2019 (Art. 152-158) and operationalised by Décret n° 2019-1590 du 31 décembre 2019 (in force 1 April 2020) with implementing Arrêté du 31 décembre 2019. The regime requires prior authorisation from DG Trésor for non-EU/EEA acquisitions reaching ≥25% of a French target's voting rights across 17 sensitive sectors enumerated in CMF Art. R151-3, and for ≥10% acquisitions in listed-company targets (threshold made permanent by Décret 2023-1293 from 1 January 2024, having been originally introduced during COVID-19 by Décret 2020-892). Approximately 310 notifications are received annually; the regime closes the last major G7 EU-member-state FDI-screening parent-statute gap after DE AWG §§55-62, IT Golden Power DL 21/2012, NL Wet Vifo, UK NSI Act 2021, US CFIUS, JP FEFTA, AU FATA, and CH IPG.